178 filings
8-K
ICPT
Intercept Pharmaceuticals, Inc.
8 Nov 23
Entry into a Material Definitive Agreement
4:44pm
8-K
ICPT
Intercept Pharmaceuticals, Inc.
26 Sep 23
Entry into a Material Definitive Agreement
8:28am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
2 Aug 23
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
7:05am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
23 Jun 23
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
6:35am
8-K
ICPT
Intercept Pharmaceuticals, Inc.
22 Jun 23
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
8:50pm
8-K
8k3ffv6iab3ch7
25 May 23
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
2jd3rz0 eg1
19 May 23
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
7:27pm
8-K
6akbdxf5b 1rk5
17 May 23
Entry into a Material Definitive Agreement
5:43pm
8-K
hrup3p tei
27 Apr 23
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
7:05am
8-K
7j19rso
24 Mar 23
Entry into a Material Definitive Agreement
5:18pm
8-K
e9cr h39gyf50
2 Mar 23
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance
7:05am
8-K
yww5qt
27 Feb 23
Other Events
8:00am
8-K
gka0he7j2ycczutmur
21 Feb 23
Other Events
8:00am
8-K
7noq3c09ee3 3z4p7u
2 Feb 23
Departure of Directors or Certain Officers
5:15pm
8-K
4g6mu8w4 lfc0
25 Jan 23
Other Events
8:00am
8-K
yv4395cyez11hccnnd66
19 Jan 23
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
8:05am
8-K
3o78zlgtoq
17 Jan 23
Other Events
8:00am
8-K
0fkxm gkd
11 Jan 23
Regulation FD Disclosure
8:00am
8-K
gv58 fntiac
23 Dec 22
Regulation FD Disclosure
8:00am
8-K
w2845qj5b0gwczmtcle
1 Nov 22
Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
7:05am